Sign Up for a Free Account
  • Updated 09.06.2020
  • Released 10.08.2009
  • Expires For CME 09.06.2023

Tapentadol

Introduction

Overview

Historical note and terminology

Tapentadol is a novel analgesic with combined opioid and adrenergic activity that was developed to fulfill some of the unmet needs in the management of acute pain and reduce the adverse effects of opioids. It may provide effective analgesic therapy for acute pain with both nociceptive and neuropathic components. Tapentadol immediate release (Tapentadol IR) was approved by the FDA in 2009 for the treatment of moderate to severe acute pain. It is the first new drug in the centrally acting analgesic class approved in the United States in more than 25 years. Tapentadol is listed in schedule II under the Controlled Substance Act (10). Rates of tapentadol immediate release (IR) abuse and diversion have been low during the first 2 years after its launch (09).

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com